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Abstract
A major goal of personalized medicine is to pre-symptomatically identify individuals at high risk for disease using
knowledge of each individual’s particular genetic profile and constellation of environmental risk factors. With the
identification of several well-replicated risk factors for age-related macular degeneration (AMD), the leading cause of legal
blindness in older adults, this previously unreachable goal is beginning to seem less elusive. However, recently developed
algorithms have either been much less accurate than expected, given the strong effects of the identified risk factors, or have
not been applied to independent datasets, leaving unknown how well they would perform in the population at large. We
sought to increase accuracy by using novel modeling strategies, including multifactor dimensionality reduction (MDR) and
grammatical evolution of neural networks (GENN), in addition to the traditional logistic regression approach. Furthermore,
we rigorously designed and tested our models in three distinct datasets: a Vanderbilt-Miami (VM) clinic-based case-control
dataset, a VM family dataset, and the population-based Age-related Maculopathy Ancillary (ARMA) Study cohort. Using a
consensus approach to combine the results from logistic regression and GENN models, our algorithm was successful in
differentiating between high- and low-risk groups (sensitivity 77.0%, specificity 74.1%). In the ARMA cohort, the positive and
negative predictive values were 63.3% and 70.7%, respectively. We expect that future efforts to refine this algorithm by
increasing the sample size available for model building, including novel susceptibility factors as they are discovered, and by
calibrating the model for diverse populations will improve accuracy.
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Introduction
Age-related macular degeneration (AMD) attacks the central
retina and causes debilitating vision loss in the approximately 1.5
million Americans affected by advanced forms of disease[1].Ge-
netic variants CFH Y402H[2–4], ARMS2 A69S[5,6], C3
R102G[7–9], and cigarette smoking[10] are now well-accepted
risk factors for AMD, and CFB R32Q is associated with decreased
AMD risk[11–13]. This recent success in identifying both genetic
and environmental modifiers of AMD susceptibility has prompted
the development of algorithms for identifying individuals at
particularly high risk for AMD based on some combination of
environmental and genetic risk factor data[11,14–18] (Table 1).
Comparisons between algorithms have been made difficult due to
differences in which risk factors are included in the model,
differences in the type of modeling strategy used, and the variety of
measures used to describe the success of the algorithms. However,
it is obvious that no current algorithm correctly classifies AMD
case-control status 100% of the time.
The level of accuracy needed to reach clinical utility is
debatable and depends on a variety of factors, including whether
the underlying goal is presymptomatic diagnosis or screening for
increased risk of future disease. The receiver operating character-
istic (ROC) curve plots sensitivity vs. 1-specificity and can be used
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to evaluate how well a continuous variable (e.g. probability of a
genetic disease calculated from a genetic algorithm) can discrim-
inate between binary outcomes (e.g. case-control status). A
common rule of thumb for evaluating clinical tests is that the
area under the ROC curve (AUC) should be .0.75 for screening
individuals at increased risk for disease and .0.99 for presymp-
tomatic diagnosis[19]. Of the three previous studies reporting the
AUC in AMD, all exceeded the threshold set for screening[16–
18], though the authors were cautious in raising the possibility that
an accurate genetic test for AMD could be developed. An
absolutely critical step for gauging the clinical utility of any
algorithm is to determine its accuracy in a completely untested
dataset of individuals at risk for AMD. This step mimics the
situation that would occur should an algorithm begin to be used in
clinical practice, and the importance of performing this validation
step cannot be overstated. To our knowledge, none of these studies
tested their models in an independent dataset. The single study
that did have separate training and testing datasets reported 70%
sensitivity and 50% specificity in their testing dataset[11]. While
this represents unprecedented success in modeling a complex
genetic disease and would potentially be useful in identifying high-
risk persons, a specificity of 50% makes a ‘‘low-risk’’ result difficult
to interpret.
Therefore, in developing a new algorithm, our goals were
twofold: 1) to increase the accuracy to a level approaching clinical
usefulness, and 2) to carry out a true test of model validation by
thoroughly testing the new algorithm in an independent,
population-based dataset. We chose to model the effects of age,
smoking, CFH Y402H, ARMS2 A69S, C3 R102G, and CFB
R32Q using logistic regression, multifactor dimensionality reduc-
tion (MDR), and grammatical evolution of neural networks
(GENN) in multiple distinct datasets. First, we constructed these
models in 4/5 of the Vanderbilt-Miami (VM) case-control study
population and then tested the models on the remaining 1/5 of
this dataset and another VM dataset of families containing
multiple affected individuals. For a more rigorous test of how the
models would perform in the population as a whole, we then
applied them to the Age-Related Maculopathy Ancillary (ARMA)
Study, which was drawn primarily from the Health ABC cohort, a
population-based longitudinal study of highly functional elderly
individuals randomly selected from Medicare roles in Memphis,
TN. Among other measures, overall correct classification rate,
AUC, positive predictive value (PPV), and negative predictive
value (NPV) were used to evaluate the success of the models in this
final testing set.
Methods
Ethics Statement
Approval for the study was obtained from Institutional Review
Boards at VanderbiltUniversity, University of Miami, and
University of Tennessee Health Science Center. All study
participants gave written informed consent to participate in this
study, and this research adhered to the tenets of the Declaration of
Helsinki.
Study Populations
It is essential to construct a model in one dataset and then apply
the model in a separate dataset to avoid bias in model evaluation.
With this in mind, we initially used one dataset for training
(referred to as the Vanderbilt-Miami (VM) training dataset), and
three independent datasets for testing (the VM testing dataset, the
VM family dataset, and the ARMA Study). Later, the analyses
were reversed with the ARMA dataset being used for training and
the VM datasets used for testing.
The VM training dataset was formed by randomly selecting 4/5
of the AMD cases (n = 349) and 4/5 of the controls (n = 216) with
complete risk factor data, who were ascertained through
ophthalmology clinics at Vanderbilt and Duke University Medical
Centers. The remaining 1/5 cases (n = 87) and 1/5 controls
(n = 54) were assigned to the VM testing dataset. The VM family
dataset was used only for testing the models and consisted of 226
families with multiple affected individuals and their unaffected
relatives. There was no overlap of individuals between the VM
training, testing, and family datasets. Individuals not of European
descent (n = 33) were excluded from analysis due to the small
sample size and because allele frequencies of some AMD-
associated variants differ by ancestry[20]. All patients and controls
received an eye exam and had stereoscopic fundus photographs
graded according to a modified version of the Age-Related Eye
Disease Study (AREDS) grading system as described elsewhere
[21,22]. Briefly, grades 1 and 2 represent controls. Grade 1
controls have no evidence of drusen or small non-extensive drusen
without pigmentary abnormalities, while grade 2 controls may
Table 1. Previous studies that developed an AMD algorithm.
Reference Factors in the Model Method(s) Used
Independent Dataset
for Validation? Sensitivity Specificity AUC
Gold et al. 2006[11] CFH, C2, CFB Genetic Algorithm yes 0.74 0.56 .
Hughes et al. 2007[14] CFH, ARMS2, smoking risk score no . . .
Jakobsdottir et al.
2008[15]
CFH, ARMS2, C2, CFB logistic regression no . . .
Jakobsdottir et al.
2008[15]
CFH, ARMS2, C2, age,
gender, smoking
Generalized MDR no 0.70 0.74 .
Jakobsdottir et al.
2009[16]
CFH, ARMS2, C2 logistic regression no . . 0.79
Seddon et al. 2009[17] CFH, ARMS2, C2, CFB, C3,
CFH*supplement treatment group,
age, gender, education, baseline
AMD grade, smoking, BMI
logistic regression no . . 0.83
Gibson et al. 2010[18] CFH, ARMS2, C3, SERPING1, age,
gender, smoking
logistic regression no 0.76 0.76 0.83
doi:10.1371/journal.pone.0017784.t001
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show signs of either extensive small drusen or non-extensive
intermediate drusen and/or pigmentary abnormalities. Grade 3
AMD cases have extensive intermediate drusen or large, soft
drusen with or without drusenoid retinal pigment epithelial
detachment. Grade 4 AMD cases exhibit geographic atrophy
and grade 5 individuals have exudative AMD, which includes
nondrusenoid retinal pigment epithelial detachment, choroidal
neovascularization, and subretinal hemorrhage or disciform
scarring. Individuals were classified according to status in the
more severely affected eye.
The ARMA samples (n = 85 cases, 148 controls) were part of
a prospective cohort from Memphis, TN, aged 70 or older. The
vast majority of participants (86%) were from the Memphis
Health ABC study, which included individuals who did not have
difficulty walking a quarter of a mile or climbing a flight of stairs
at the time of study enrollment[23,24]. The others were drawn
from the general Memphis population ascertained by self-
referral in response to advertising and presentations at
community establishments for the elderly. Because differences
in allele frequencies between ethnic groups have been reported
for some of the genetic variants used in our models,[20] and
there was an insufficient number of blacks available in the VM
dataset on which to build a model (n = 3 with complete risk
factor data), blacks in the ARMA cohort were not included in
any analyses.
Large variation in the demographic characteristics of the
training and testing datasets, though informative about how well
these models may apply to a general population, will reduce the
number of individuals correctly classified in the testing dataset.
Therefore, we carefully compared the testing and training datasets
to determine if they differed substantially for any important
demographic traits (Table 2).
Genotyping
CFH Y402H (rs1061170), ARMS2 A69S (rs10490924), CFB
R32Q (rs641153), and C3 R102G (rs2230199) were genotyped as
part of a Sequenom iPLEXH Goldpool, according to the
manufacturer’s instructions. Three quality control samples were
duplicated within and between plates, and genotypes were checked
for concordance. All genetic variants had a genotyping efficiency
rate of at least 95%. Because the algorithm requires complete risk
factor information, the few samples that did not have complete
genotype information were dropped from analysis. All SNPs were
verified to be in Hardy-Weinberg equilibrium in controls.
Building the Models
Logistic regression, MDR, and GENN were used to build
models of AMD. For the logistic regression analyses, we included
age of examination (in years), smoking (coded ‘‘1’’ for those who
had smoked at least 100 cigarettes, ‘‘0’’ for those who reported
never smoking or smoking less than 100 cigarettes), and CFH
Y402H, ARMS2 A69S, CFB R32Q, and C3 R102G (using
additive encodings for all genetic variants) in the model. Though
other environmental variables (e.g. sex and body mass index
(BMI)[25]) and genetic variants (e.g. polymorphisms in or near the
CFI[26], LIPC[27], and TIMP3[28] genes) may also be associated
with AMD, we chose not to include them in the model, primarily
for two reasons: 1) to minimize the number of parameters the
model estimated we chose only the most robustly associated
genetic and environmental factors with the greatest effect sizes,
and 2) some of the modeling methods we wanted to test (e.g.
MDR) perform optimally with categorical variables, rather than
quantitative traits like BMI. Therefore, the logistic regression
equation was:
g~b0zb1  Agezb2  Smokingzb3  CFH
zb4  ARMS2zb5  CFBzb6  C3
and a rough estimate of the probability of AMD for an individual
can be calculated as:
rough estimate of probability of AMD~
eg
1zeg
Based on the size of the available datasets, we did not include
interactions terms in the model, thereby reducing the number of
parameters that have to be estimated. Once the rough estimate of
probability of AMD was determined for each individual in the
testing dataset, individuals with a probability greater than a
particular threshold were classified as ‘‘high-risk’’, and those below
the threshold were classified as ‘‘low-risk’’. These ‘‘model calls’’
were then compared to the affection status assigned by a clinician,
and the sensitivity, specificity, positive predictive value, negative
predictive value, and overall correct classification rate of the model
were determined. Changing the threshold for the probability of
AMD will change the number of false positives and false negatives
called by the model. Because there was no a priori reason to select
a particular threshold value, we chose 0.5 as a cut-off for our
analyses. After examining the histogram of AMD probabilities by
Table 2. Characteristics of the datasets.
Characteristic VM Training VM Testing VM Families ARMA p-value VM Training vs. ARMA
Cases/Affecteds (#) 349 87 326 85 NA
Controls/Unaffecteds (#) 216 54 86 148 NA
Age of exam [mean (sd)] 73.5 (8.4) 73.1 (8.3) 72.8 (9.4) 79.3 (3.6) ,0.0001
Gender (% Female) 61.1 59.6 67.0 51.5 0.01
% ever Smokers 52.0 56.0 54.6 50.2 0.64
CFH frequency C allele 50.6 48.9 61.9 42.9 0.01
ARMS2 frequency T allele 35.7 31.2 42.4 23.8 ,0.0001
CFB frequency A allele 6.8 7.1 5.2 9.7 0.05
C3 frequency C allele 25.3 26.2 29 25.5 0.93
doi:10.1371/journal.pone.0017784.t002
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true affection status, we raised the threshold to 0.75 in the ARMA
testing dataset in an attempt to increase accuracy. Finally, we used
ROC curves (plots of sensitivity vs. 1-specificity) to determine the
threshold that would have correctly classified the greatest number
of individuals.
For MDR, the number of cases and controls with each
particular susceptibility factor combination was calculated. If the
ratio of cases to controls having this combination in the training
dataset exceeded the total ratio of cases and controls, then
individuals with the same combination in the testing dataset were
called ‘‘high-risk’’. Otherwise, individuals were called ‘‘low-risk’’.
This is the usual metric used to classify individuals as ‘‘high-’’ or
‘‘low-risk’’ by the MDR method[29], and MDR software[30] was
used to generate the counts of cases and controls with each
combination of susceptibility factors in the training dataset.
However, this does not exactly correspond to a ‘‘traditional’’
MDR analysis because: 1) we a priori forced MDR to include our
variables of interest, rather than allowing the software to perform
variable selection and 2) we used completely independent datasets
for testing rather than cross validation. We included smoking and
the CFH, ARMS2, CFB, and C3 variants in the model. Because
MDR works best with susceptibility factors that have only a few
levels, and because we wanted to maintain comparability with the
logistic regression analyses, age of exam was included in the model
coded ‘‘1’’ for individuals in the lowest quantile of age of exam,
‘‘2’’ for those in the second quantile, and so on. One advantage of
this type of MDR model compared to logistic regression is that
there is no need to specify an arbitrary threshold value for
classifying risk status. The major drawbacks are: 1) age cannot be
included in the model as a continuous variable without overly
stratifying the datasets and 2) large sample sizes are needed for
each susceptibility combination to ensure stability of the model.
Grammatical Evolution of Neural Networks (GENN) has been
extensively described[31]. Briefly, neural networks are a robust
and flexible modeling strategy, consisting of input layers, hidden
layers, and an output layer. Each layer contains various nodes
connected by arcs and weighted by some arithmetic function.
When the input data exceed some threshold, the neural network
‘‘fires’’. The goal in our case was to classify individuals as high- or
low-risk for AMD (the output) from genetic and clinical risk factor
data (the inputs). The architecture of the neural network (how the
nodes are connected, the weights on each node, etc.) was
optimized using the process of grammatical evolution. Grammat-
ical evolution begins with an initial random set of neural network
architectures, and the neural networks with the best fitness
(measured in this application by balanced accuracy[32]) are
propagated to the next generation. Random ‘‘mutation’’ and
‘‘crossover’’ events in subsequent generations allow the neural
networks to evolve, and hopefully, reach a final architecture that is
useful in classifying AMD risk level. To maintain comparability
with the other modeling strategies used, we included age of exam
(in quantiles), smoking, and CFH Y402H, ARMS2 A69S, CFB
R32Q, and C3 R102G as inputs for the neural networks. Only
neural networks that contained all 6 factors exactly once were
propagated to the next generation (effectively allowing for
optimization of the weights and arcs, but not allowing variable
selection). The parameter settings for the evolution of the neural
networks were a ‘‘genome size’’ ranging from 25–1000 bits, using
a population size of 5000 ‘‘genomes’’, with probability of a
crossover event set to 0.9, and probability of mutation set to 0.01.
After optimization of the neural networks in the training dataset,
the final best neural network model, as measured by balanced
accuracy in the training dataset, was applied to the testing dataset
and evaluated.
Evaluating the Models
We used AMD case-control status assigned by retinal specialists
after examination of stereoscopic fundus photographs as the gold
standard with which to compare our ‘‘model calls’’ of high- and
low-risk from the three methods. Though the possibility of
clinician misdiagnosis exists, extensive quality control measures
were taken to guard against it, including concordance checks by
multiple graders. In a previous study using a subset of the VM
datasets, concordance among graders was 92% with a kappa
statistic of 0.81, indicating excellent agreement[33].
We defined sensitivity as the number of individuals who were
truly affected with AMD and identified by the algorithm as ‘‘high-
risk’’/total number of true AMD cases as determined by clinician
grading. Specificity equals the number of individuals who were
truly unaffected and called ‘‘low-risk’’/total number of controls.
The overall correct classification rate is the number of true cases
identified as ‘‘high-risk’’ plus the number of controls identified as
‘‘low-risk’’/total number of individuals tested. PPV equals the
percentage of individuals labeled ‘‘high-risk’’ who were true AMD
cases. NPV equals the percentage of individuals labeled ‘‘low-risk’’
who were true controls. Estimates of PPV and NPV from case-
control data are often inflated[34], and can be adjusted by
considering the prevalence of the disease in the population of
interest using the following formulas:
PPV~
sensitivity|prevalence
(sensitivity|prevalence)z (1{prevalence)(1{specificity)½ 
NPV~
specificity(1{prevalence)
specificity(1{prevalence)z prevalence(1{sensitivity)½ 
As the ARMA cohort is primarily population-based, we report
only the unadjusted PPV and NPV in this dataset.
Results
Model Building in the VM Training Dataset
In the logistic regression model built in the VM training dataset,
all six susceptibility factors were significantly associated with AMD
in the direction expected from previous reports in the literature
(Table 3). In the MDR model, there was a clear tendency for
individuals with more risk alleles/risk factors present and fewer
protective alleles to be classified by the model as ‘‘high-risk’’ and
vice versa, as expected (data not shown). GENN separated the
genetic risk factors and the environmental risk factors into two
separate hubs (Figure S1). Of the genetic factors, GENN weighted
CFH Y402H and ARMS2 A69S most heavily, followed by C3
R102G and CFB R32Q. This ranking of the genetic susceptibility
factors mimics the frequency of these factors in our training
dataset. However, it is difficult to infer the relative importance of
each factor to disease from the GENN weights alone because the
weights will change with tweaks to the architecture of the neural
network.
Models Built in the VM Training Dataset Applied to VM
Testing and VM Family Datasets
Of the three methods, the GENN model performed the best
when applied to the VM testing dataset with an overall correct
classification rate of 80.1% (Table 4). GENN correctly classified
more cases than controls (83.9% sensitivity vs. 74.1% specificity).
The logistic regression model was slightly less successful than
Identifying Individuals at High Risk for AMD
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GENN (77.3% overall correct), and followed the same trend of
higher classification rates for cases than controls. The area under
the ROC curve was 0.84 (95% confidence interval 0.81 to 0.88,
Figure S2), which exceeded both the AUC for previously
developed similar algorithms (Table 1) and the recommended
cutoff for screening high-risk individuals[19].
The MDR method did much worse than GENN and logistic
regression with only 59.6% of individuals classified correctly and
20.6% of the individuals not classified at all (denoted ‘‘CNC’’ for
could not classify). When a particular combination of susceptibility
factors is not observed in the training dataset, no decision rule can
be made, and therefore all individuals with that combination in the
testing dataset are CNC. Given the sample size of the available
datasets and the number of factors in the model, the somewhat
decreased performance of the MDR model is not unexpected.
We also examined the agreement between the three methods
using a consensus approach that gives individuals a ‘‘high-risk’’ call
only when at least 2 of the 3 methods indicate increased risk and a
‘‘low-risk’’ call otherwise. Taking the consensus of all three
methods or of the two best-performing individual methods (logistic
regression and GENN) classified fewer people correctly than using
GENN alone and did not improve either the sensitivity or
specificity.
Naı¨ve estimates of PPV and NPV are known to be inaccurate
when calculated from case-control data[34]. We compared the
naı¨ve estimates to adjusted estimates using prevalence rates of
5.5% and 15% (Table 5). As expected, the PPV for each method
decreased, ranging from 12.3 to 17.6 at a prevalence of 5.5% and
from 29.9 to 39.4% at a prevalence of 15%. Notably, the NPV
increased substantially, exceeding 94% for all methods tested at
both prevalence rates.
We next applied the same model to a testing dataset composed
of families with multiple members affected by AMD. In the family
data, logistic regression performed best overall, but only by a small
margin over GENN (overall correct classification rates of 76.9%
and 73.3%, respectively, Table S1). Logistic regression was more
sensitive than GENN, but less specific (sensitivity 84.0% vs. 76.1%,
specificity 50.0% vs. 62.8%, respectively). MDR again had the
poorest accuracy of the three methods (overall correct classifica-
tion 71.4%) with a similar proportion of individuals called CNC
(17.7%). Taking the consensus of logistic regression and GENN
improved the specificity compared to each single method alone
(69.8%), at the expense of lower sensitivity than either single
method (74.5%).
Models Built in the VM Training Dataset Applied to the
ARMA Dataset
For a more realistic measure of how these models apply to the
general population, we tested them in the ARMA dataset. As
expected, the classification rates did decrease, but were still better
than chance. Because the optimal threshold for the probability
cutoff in logistic regression is likely to vary by dataset and this
threshold cannot be determined in advance, we examined three
cut-offs: 1) 0.5, chosen for comparison with the VM testing dataset
analysis 2) 0.75, chosen after examining a histogram of
probabilities by clinician-assigned affection status (data not shown),
and 3) 0.87, chosen because this was the optimal threshold in the
ARMA dataset determined by ROC analysis (Figure S3). Using
the optimal 0.87 threshold, 69.1% of individuals were correctly
classified yielding a sensitivity of 36.5% and specificity of 87.8%
(Table 6). Obviously, decreasing the threshold resulted in
suboptimal classification rates: 60.5% overall correct for a
threshold of 0.75 and 48.9%, worse than chance, for a threshold
of 0.5. This suggests that if the logistic model were to be applied to
a new population, a sample of that population would need to be
tested and the model carefully calibrated before widespread use.
Model calibration strategies have been successfully used to adjust
an algorithm for coronary heart disease that was created in the
Framingham Heart Study for application in six other ethnically
diverse cohorts[35], and we expect that using a similar approach
would increase the accuracy of our algorithm in other populations.
Somewhat surprisingly, the GENN model, which performed the
best in the VM testing dataset, was not as successful in the ARMA
dataset (51.1% overall correct). Though quite good at identifying
cases (76.5% sensitivity), the method was hampered by poor
Table 3. Logistic regression model in the VM training dataset.
Factor Coefficient p-value
Odds
Ratio
95% Confidence
Interval
Age 0.13 ,0.001 1.13 1.10 1.17
Smoking 0.48 0.026 1.61 1.06 2.45
CFH Y402H 1.04 ,0.001 2.84 2.07 3.90
ARMS2 A69S 0.69 ,0.001 2.00 1.47 2.72
CFB R32Q 21.10 ,0.001 0.33 0.18 0.60
C3 R102G 0.41 0.014 1.51 1.09 2.11
Constant 210.48 ,0.001 . . .
doi:10.1371/journal.pone.0017784.t003
Table 4. Classification rates using the VM training dataset for training and VM testing dataset for testing.
Method Sensitivity Specificity Unadjusted PPV Unadjusted NPV % Overall Correct
LR [0.5] 85.1 64.8 79.6 72.9 77.3
MDR 71.8 (58.6) 80.5 (61.1) 86.4 (NA) 62.3 (NA) 75.0 (59.6)
GENN 83.9 74.1 83.9 74.1 80.1
Consensus–LR, MDR, GENN 82.8 74.1 83.7 72.7 79.4
Consensus–LR, GENN 77.0 74.1 82.7 66.7 75.9
PPV =positive predictive value, NPV=negative predictive value, NA= not applicable, LR = logistic regression. Logistic [0.5] indicates the threshold used for determining
model calls in the logistic regression analysis. In this case, all individuals with probabilities $0.5 were given a model call of ‘‘high-risk’’. For MDR 20.6% of the testing
dataset could not be classified. The first entry in the table represents the classification rate considering only the individuals that could be classified in the denominator.
The number in parentheses gives the classification rate considering the entire testing dataset as the denominator. For example, using MDR, 71 individuals who were
actually cases could be classified and of those 51/71 = 71.8% were correctly classified as ‘‘high-risk’’. Considering all cases that were tested, 51/87 = 58.6% were correctly
classified. For the consensus of methods, individuals were called high-risk only if two or more methods classified them as high-risk.
doi:10.1371/journal.pone.0017784.t004
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performance in controls (36.5% specificity). MDR was again the
worst with an overall classification rate of 45.5%, and leaving
18.0% of the data unclassified.
Taking the consensus of logistic regression with the optimal
threshold and GENN resulted in the same sensitivity, specificity,
and overall classification rate as using logistic regression with the
optimal threshold alone (Table 6), as everyone called high-risk by
logistic regression was also labeled high-risk by GENN. Interest-
ingly, if model calibration cannot be performed and we must use
the arbitrary threshold of 0.5 for logistic regression, then taking the
consensus of logistic regression and GENN is more successful than
either method individually.
As a final check of how well the models would apply in
population-based data, we removed all individuals ascertained in
the ARMA cohort who were not part of the Health ABC Study.
This produced very similar results for all methods (Table S2).
Logistic regression at the optimal threshold again had the highest
overall classification rate (70.4%). Assuming no prior knowledge of
the optimal threshold for logistic regression, the most successful
algorithm was again taking the consensus of logistic regression at a
threshold of 0.5 and GENN.
Comparison of VM Training Dataset to the ARMA Dataset
The VM training and ARMA datasets were ascertained using
very different strategies. The VM training dataset was drawn from
ophthalmology, primarily retinal, clinics. The ARMA dataset was
primarily drawn from the Memphis Health ABC cohort, which
randomly sampled those on Medicare rolls. The VM training
dataset had a higher percentage of females, a higher frequency of
CFH and ARMS2 risk alleles, and a lower percentage of CFB
protective alleles (Table 2), as might be expected when comparing
a clinic-based group to the general population. However, though
these differences are not unexpected, they still negatively affect
performance of all three methods, and partially explain the
decreased accuracy observed in the ARMA dataset.
Model Building in the ARMA Dataset
Next, we rebuilt the model using the ARMA dataset.
Unfortunately, with 85 cases, most of whom were AREDS
category 3 (i.e., not advanced AMD), and 148 controls, the ARMA
dataset was somewhat underpowered to detect significant effects of
all the established AMD susceptibility factors we studied. This was
especially apparent in the logistic regression analysis, where only
CFH Y402H and CFB R32Q were significantly associated with
AMD risk (Table 7). The sparseness of data would also be
expected to have a detrimental effect on the other 2 methods,
especially MDR, which depends on large numbers of observations
for each combination of susceptibility factors to ensure stability of
the model. Nonetheless, we still observed a clear trend for those
carrying more risk factors and fewer protective CFB alleles to be
called ‘‘high-risk’’ by MDR. The neural network model was
remarkably similar to the model produced in the VM training
dataset, with the network again containing separate hubs for
Table 5. Comparison of adjusted and unadjusted PPV and NPV in the VM testing dataset.
Method Unadjusted PPV Unadjusted NPV
Adjusted PPV at
Prev=5.5%
Adjusted NPV at
Prev =5.5%
Adjusted PPV at
Prev=15%
Adjusted NPV at
Prev=15%
LR 0.5 79.6 72.9 12.3 98.7 29.9 96.1
MDR 86.4 62.3 17.6 98.0 39.4 94.2
GENN 83.9 74.1 15.9 98.8 36.4 96.3
Consensus–LR, MDR, GENN 83.7 72.7 15.7 98.7 36.1 96.1
Consensus–LR, GENN 82.7 66.7 14.8 98.2 34.4 94.8
Prev = Prevalence.
doi:10.1371/journal.pone.0017784.t005
Table 6. Classification rates using the VM training dataset for training and the ARMA dataset for testing.
Method Sensitivity Specificity Unadjusted PPV Unadjusted NPV % Overall Correct
LR [0.5] 89.4 25.7 40.9 80.9 48.9
LR [0.75] 62.4 59.5 46.9 73.3 60.5
LR [0.87, Optimal) 36.5 87.8 63.3 70.7 69.1
MDR 68.5 (58.8) 31.4 (25.0) 38.2 (NA) 61.7 (NA) 45.5 (37.3)
GENN 76.5 36.5 43.6 73.0 51.1
Consensus–LR [0.5], MDR, GENN 77.6 33.8 40.2 72.5 49.8
Consensus–LR [0.5], GENN 74.1 41.9 42.3 73.8 53.6
Consensus–LR [0.75], MDR, GENN 64.7 53.4 44.4 72.5 57.5
Consensus–LR [0.75], GENN 61.2 59.5 46.4 72.7 60.1
Consensus–LR [0.87], MDR, GENN 60.0 58.1 45.1 71.7 58.8
Consensus–LR [0.87], GENN 36.5 87.8 63.3 70.7 69.1
Logistic [0.87 Optimal] indicates that the threshold that would correctly classify the most individuals as determined by the ROC curve was applied to the testing dataset.
See notes accompanying Table 4 for further explanation.
doi:10.1371/journal.pone.0017784.t006
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genetic and environmental susceptibility factors, and the same
ranking of weights given to the genetic risk factors (Figure S4).
Models Built in the ARMA Dataset Applied to the VM
Datasets
Since the VM training and testing datasets were created by
randomly assigning 4/5 of individuals for training and 1/5 for
testing, we combined them for the purposes of creating a testing
dataset for models built in the ARMA dataset. Using a probability
threshold of 0.5, logistic regression correctly classified 59.3% of
individuals. Decreasing the threshold drastically improved perfor-
mance. Using the optimal threshold of 0.30 determined by the
ROC curve (Figure S5), 76.2% of individuals were correctly
classified (79.6% sensitivity, 70.7% specificity, Table 8). GENN
performed better than logistic regression using the arbitrary 0.5
threshold with 63.0% of individuals correctly classified, but was
not as successful as logistic regression using the optimal threshold.
MDR performed poorly, leaving 57.2% of the data unclassified,
and only correctly classifying 49.0% of individuals who were given
a result. Taking the consensus of logistic regression and GENN did
not provide a better overall classification rate than using logistic
regression with the optimal threshold alone, but did increase the
specificity (79.6%) at the cost of lowering sensitivity (61.2%).
Discussion
Many strategies have been used by our group and others to
identify individuals at elevated risk for AMD. Whenapplying a
model to a new dataset, we have seen that taking the consensus of
logistic regression and GENN models maximizes the overall
classification rate compared to any single method, when the
optimal threshold for logistic regression is not known. Using this
approach we classified individuals into ‘‘high-‘‘ or ‘‘low-risk’’
groups, with overall correct classification rates of ,76% in the
VM testing data and nearly 70% in the ARMA cohort. These
numbers are impressive, but PPV (the percentage of individuals
labeled ‘‘high-risk’’ who are actually cases) and NPV (the
percentage of individuals labeled ‘‘low-risk’’ who are actually
controls) are generally more informative when considering the
potential clinical usefulness of a new algorithm. Because of the
difficulty in accurately estimating PPV and NPV in case-control
data, it is essential to validate models in population-based cohorts.
In the ARMA cohort, using logistic regression alone produced
identical PPV and NPV results (,63% and,71%, respectively) as
taking the consensus of logistic regression and GENN models
when the optimal threshold for logistic regression was used.
Remarkably, even using the arbitrary 0.5 threshold for logistic
regression, when taking the consensus with GENN, the PPV
(,42%) and NPV (,74%) were still quite high.
To put our results in perspective, we compared them to three
other screening tools commonly used in clinical practice: the
prostate-specific antigen (PSA) and digital rectal exam (DRE) for
prostate cancer and mammography for breast cancer. A recent
meta-analysis estimated the sensitivity, specificity, and PPV for
PSA at 72.1%, 93.2%, and 25.1%, respectively and at 53.2%,
83.6%, and 17.8% for DRE[36]. Practically speaking, this means
that out of all individuals with an abnormal PSA or DRE result,
only about 1 in 4 or 5 actually has prostate cancer. When the PSA
and DRE are normal, ,90% are cancer-free[36]. Despite the low
PPV, the American Cancer Society recommendsthat physicians
counsel men over 50who are expected to live at least 10 years
about the benefits and risks of PSA tests and DRE and begin
counseling at age 40–45 for men in certain high-risk groups[37].
In a review conducted for the U.S. Preventive Services Task
Force, first mammography sensitivity ranged from 71–96%,
specificity for a single mammographic exam ranged from 94–
97%, and the PPV ranged from 2–22% for abnormal results that
led to further evaluation and 12–78% for abnormal results leading
to biopsy[38]. Again the PPV values are surprisingly low, but the
justification for regular mammograms is bolstered by additional
studies demonstrating lower mortality rates from breast cancer
among women who undergo regular screening. Comparable
prospective studies in AMD would need to show that being able to
identify high-risk individuals leads to better visual outcomes before
widespread screening would be recommended. Such studies, to
Table 7. Logistic regression model in the ARMA dataset.
Factor Coefficient p-value
Odds
Ratio 95% Confidence Interval
Age 0.05 0.22 1.05 0.97 1.14
Smoking 0.41 0.16 1.51 0.85 2.68
CFH Y402H 0.73 ,0.0001 2.08 1.39 3.11
CFB R32Q 20.96 0.02 0.38 0.17 0.86
ARMS2 A69S 0.37 0.12 1.45 0.91 2.31
C3 R102G 20.03 0.89 0.97 0.61 1.53
Constant 25.45 0.10 . . .
doi:10.1371/journal.pone.0017784.t007
Table 8. Classification rates using the ARMA dataset for training and VM training combined with VM testing as the testing dataset.
Method Sensitivity Specificity Unadjusted PPV Unadjusted NPV % Overall Correct
LR [0.5] 37.4 94.8 92.1 48.4 59.3
LR [0.30 Optimal] 79.6 70.7 81.5 68.2 76.2
MDR 48.8 (24.1) 49.4 (15.9) 70.5 (NA) 28.1 (NA) 49.0 (21.0)
GENN 65.4 59.3 72.2 51.4 63.0
Consensus–LR [0.5], MDR, GENN 42.7 90.0 87.3 49.3 60.8
Consensus–LR [0.5], GENN 35.6 94.8 91.7 47.7 58.2
Consensus–LR [0.3], MDR, GENN 65.4 75.9 81.4 57.6 69.4
Consensus–LR [0.3], GENN 61.2 79.6 82.9 56 68.3
For MDR 57.2% of the testing dataset could not be classified. The first entry in the table represents the classification rate considering only the individuals that could be
classified in the denominator. The number in parentheses gives the classification rate considering the entire testing dataset as the denominator.
doi:10.1371/journal.pone.0017784.t008
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our knowledge, have not been conducted for any of the AMD
algorithms described in the literature.
Ultimately, the decision to use a particular algorithm in clinical
practice is a judgment call that must balance the need to flag all
potentially high-risk persons with the cost of falsely labeling some
low-risk individuals as high-risk. Extensive clinical validation
studies, in particular applying potential algorithms to prospective
cohorts, need to be implemented. Furthermore, many other
factors besides clinical validity also deserve significant attention,
including the cost of screening and what can be done to help those
who are classified as high-risk to prevent disease. Though we
believe that it is premature to introduce such an AMD algorithm
to the clinic now, these results demonstrate promise for the
potential of genetic variants in predicting individual risk for
disease.
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